ASSEMBLY BIOSCIENCES,INC. (NASDAQ:ASMB) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
The following proposals were submitted to the stockholders at the
2017 Annual Meeting of Stockholders (the Annual Meeting) of
Assembly Biosciences, Inc. (the Company) held on June 1, 2017:
(i)The election of each of the Companys seven nominees for the
Board of Directors to serve until the 2018 annual meeting of
stockholders and until his successor is duly elected and
qualified or until his earlier death, resignation or removal;
(ii) The approval of a non-binding, advisory resolution approving
the compensation of the Companys named executive officers; and
(iii)The ratification of the selection of Ernst Young LLP as the
Companys independent registered public accounting firm for the
Companys fiscal year ending December31, 2017.
The proposals are described in detail in the Companys Proxy
Statement filed with the Securities and Exchange Commission on
April 21, 2017.
The number of shares of common stock entitled to vote at the
Annual Meeting was 17,305,044. The number of shares of common
stock present or represented by valid proxy at the Annual Meeting
was 13,985,926. All matters submitted to a vote of the Companys
stockholders at the Annual Meeting were approved and all director
nominees were elected.
The number of votes cast for and against and the number of
abstentions and broker non-votes with respect to each matter
voted upon are set forth below:
| (a) | Election of Directors. |
| DirectorNominee | VotesFor | VotesWithheld | ||
| Anthony E. Altig | 12,570,994 | 4,188 | ||
| Mark Auerbach | 12,571,799 | 3,383 | ||
| Richard DiMarchi, Ph.D. | 12,572,099 | 3,083 | ||
| Myron Z. Holubiak | 12,570,794 | 4,388 | ||
| Alan J. Lewis, Ph.D. | 12,570,794 | 4,388 | ||
| William R. Ringo, Jr. | 12,306,535 | 268,647 | ||
| Derek A. Small | 12,572,099 | 3,083 |
There were 1,410,744 broker non-votes regarding the election of
directors.
| (b) | Non-Binding Advisory Resolution on Executive Compensation. |
Stockholders approved the non-binding, advisory resolution
approving the compensation of the Companys named executive
officers. The results of the voting included 12,548,520 votes
for, 13,935 votes against, and 12,727 votes abstained.
There were 1,410,744 broker non-votes regarding this proposal.
| (c) |
Ratification of Selection of Independent Registered Public Accounting Firm. |
Stockholders ratified the selection of Ernst Young LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017. The results of the voting
included 13,974,440 votes for, 1,628 votes against, and 9,858
votes abstained.
There were no broker non-votes regarding this proposal.
About ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections. ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB) Recent Trading Information
ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB) closed its last trading session down -0.31 at 25.65 with 40,752 shares trading hands.
